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INTRODUCTION
Nuclear cardiology has undergone an outstanding growth during the 
last 25 years.
With technical improvements and new radiopharmaceuticals, higher 
sensitivity and specifi city of myocardial perfusion imaging (MPI) scans 
has been achieved for detection and evaluation of ischemic heart 
disease.  
MPI is performed with the administration of radiopharmaceuticals 
which are taken up by the myocardial cells.  Different radiotracers can 
be used, such as: Thallium-201, 99mTc-Sestamibi, 99mTc-Tetrofosmin, etc. 
The investigation is performed at rest and stress, providing semi-
quantitative information on areas of myocardial infarction and 
ischemia.  
Beller et al. showed in the “anginal cascade”(1) that, with increasing stress 
time and myocardial oxygen demand, ischemic ST depression and 
anginal symptoms appear after fl ow heterogeneity, regional myocardial 
dysfunction, signifi cant perfusion defects and global left ventricular 
dysfunction. This accounts for the increased sensitivity, specifi city and 
accuracy of MPI over symptoms and stress ECG in the diagnosis and 
follow-up of coronary artery disease.
It has developed into one of the most contributory fi elds in clinical 
decision making for the detection and risk stratifi cation in patients with 
suspected and known coronary artery disease. 
USE OF MYOCARDIAL PERFUSION SCINTIGRAPHY 
IN THE CLINICAL SETTING
Myocardial perfusion SPECT (single photon emission computed 
tomography) is a widely utilized noninvasive imaging modality for the 
diagnosis and management of ischemic heart disease. This modality 
allows a three-dimensional assessment and quantitation of the 
myocardium and functional assessment through ECG-gating of the 
perfusion images.(2) 
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Nuclear cardiology has developed into 
an extremely valuable tool for the diagnosis and 
prognostication of coronary artery disease.  With the low 
sensitivity and specifi city of clinical symptoms, baseline and 
stress ECG, physicians and cardiologists require non-
invasive techniques to detect and risk stratify patients with 
ischemic heart disease. Myocardial perfusion imaging 
(MPI) achieves great accuracy in the diagnosis of the disease 
and in identifying the patients with higher risk for adverse 
events. Literature shows that it is not the coronary anatomy 
but the ischemic burden that determines prognosis in 
patients with ischemic heart disease. Patients with normal 
MPI, independently of age, gender, symptoms, history of 
coronary artery disease, presence of anatomic coronary 
artery disease (CAD) or isotope or imaging technique, 
have a <1% risk of adverse events (myocardial infarction or 
cardiac death) for a period of at least 12 months. Left 
ventricular function, regional wall motion abnormalities as 
well as myocardial viability can be evaluated with MPI.
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There are several indications for the use of myocardial perfusion SPECT, 
whether it is for a patient who is not known to have coronary artery 
disease and the aim is confi rm or rule out the diagnosis, or in the 
patient with known ischemic heart disease, whether symptomatic or 
not, for risk-stratifi cation (Table 1).
Indications for myocardial perfusion scintigraphy 
If the patient does not have diagnosis of CAD
To exclude or diagnose CAD in patients with suspected CAD
 As a screening test in those with intermediate or high risk of CAD, 
e.g. familial hyperlipidemia, type II diabetes mellitus, family history of 
CAD, and those with atypical symptoms of ischemic heart disease 
(IHD). In patients with high pretest likelihood for CAD, MPI is 
mainly useful for risk stratifi cation purposes. 
 In patients with non-diagnostic electrocardiography (ECG), at rest 
or post-stress. While there are many causes for an abnormal 
baseline ECG (Table 2), STRESS- ECG is frequently not conclusive. 
  Gianrossi et al. performed a meta-analysis of 147 consecutive 
published reports involving 24 074 patients who underwent both 
coronary angiography and exercise testing.(3) Mean sensitivity was 
■
■
found to be 68% (range 23 to 100) while mean specifi city was 77% 
(range 17 to 100). 
 Patients who are at risk of developing peri or postoperative 
cardiovascular events, i.e. peripheral vascular disease, aortic 
aneurysm, and the elderly.
Acute chest pain – diagnosis of CAD.
LBBB can induce perfusion defect in the basal anteroseptal myocardial 
segment not attributable to CAD. This can potentially give a false 
interpretation of the scan. Specifi city is not affected when evaluating 
other myocardial segments. However, a pharmacological stress with 
MPI will still provide high sensitivity in patients with LBBB.
The sensitivity and specifi city of MPI ranges between 81% and 91% and 
between 82% and 91% respectively(4-7) for the detection of coronary 
artery disease.
Myocardial perfusion imaging is both more sensitive and more specifi c 
than exercise ECG for the diagnosis of CAD.
In patients with diagnosis of CAD
To evaluate the “functional” signifi cance of a coronary lesion 
(stenosis).
For risk stratifi cation and evaluation of prognosis. Myocardial 
perfusion scintigraphy is one of the most powerful non-invasive 
techniques for risk stratifi cation.  
The “functional” signifi cance of the extent and severity of stress 
perfusion defect is closely related to subsequent cardiac events.  
The important variables are, therefore, extent, severity and 
reversibility of a stress perfusion defect.
Detection of patients with “high risk” CAD. The factors that 
represent “high risk” stress myocardial perfusion defects are:
- Multiple defects in different vascular regions (multivessel disease).
-  Proximal left anterior descending (LAD) coronary artery disease, 
leading to reversible defects in the antero-septal and apical 
regions; reversible defects in the antero-septal and lateral wall 
may indicate left main disease or equivalent.
■
■
■
■
■
■
■
TABLE 1: Use of myocardial perfusion SPECT in the clinical setting
Diagnosis of coronary artery disease
Identify the site and extent of ischemia
Quantifi cation of the extent and severity of impaired coronary fl ow reserve
Acute ischemic syndromes
Pre-surgical evaluation
Prognostic assessment of CAD patients
Assessment of tissue viability
TABLE 2: Non-coronary causes of ST-segment depression
Severe aortic stenosis
Severe hypertension
Cardiomyopathy
Anemia
Hypokalemia
Severe hypoxia
Digitalis effect
Sudden excessive exercise
Glucose load
Left ventricular hypertrophy
Hyperventilation
Mitral valve prolapse
IV conduction disturbances (RBBB, LBBB)
Preexcitation syndrome (i.e. WPW)
Severe volume overload
Severe pressure overload
Supraventricular arrhythmias
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Perhaps the most consistent observation in the literature concerning 
the prognostic value of MPI is that the presence and extent of 
transient myocardial perfusion imaging defects, a marker of 
jeopardized viable myocardium, predict important future cardiac 
events.
In 1983, Brown et al. compared 201TI with clinical, exercise ECG, and 
angiographic data in patients without known previous MI who 
presented for evaluation of chest pain. The best predictor of cardiac 
death or non-fatal MI was the number of myocardial segments with 
transient defects on 201TI imaging.(8)
Although the presence of jeopardized viable myocardium identifi es 
patients at increased risk for cardiac events, more importantly 
cardiac risk is directly related to the extent of jeopardized viable 
myocardium.
Post-infarction risk stratifi cation
Detection of ischemia at the site of injury or remotely. 
Evaluate for myocardial viability in the infarct region.
Evaluate the fl ow-function relationship (from gated SPECT). 
Selection of patients for medical treatment versus revascularization 
in stable angina.
Major determinants of prognosis after myocardial infarction patients 
are infarct size, left ventricular ejection fraction and the presence or 
absence of distant residual ischemia. All these variables can be 
determined with 99mTc-Sestamibi, Tetrofosmin, Thallium-201 (and 
other tracers) scintigraphy.
After Percutaneous Transluminal Coronary Angioplasty (PTCA)
Restenosis after PTCA occurs in 30-40%(9-12) of cases but may remain 
asymptomatic for long periods. However, since the advent of 
intracoronary stenting, this rate has signifi cantly decreased.(13) Perfusion 
imaging is superior to clinical and other non-invasive tests for detecting 
restenosis. Serial imaging at 6 weeks, 3-6 months, and then according to 
the clinical situation may be necessary for optimal monitoring of 
PTCA.
In a study done in Johannesburg, South Africa, 122 patients at least 
3 months after PCI (percutaneous coronary interventions) underwent 
myocardial perfusion scintigraphy. Ischemia was found in 56% of 
■
■
■
■
asymptomatic patients,(14) which was in keeping with other reports 
which showed clinically silent restenosis in 60% of patients with ischemia 
on MPI.(15) Regardless of whether restenosis was silent or symptomatic, 
an abnormal MPI post PTCA was associated with increased risk for 
hospital admission or myocardial infarction.(15)
Normal MPI post coronary angioplasty indicates:
That the procedure was successful. 
That there is low risk for recurrent cardiac events.(15,16)
Low probability of late restenosis.(16)
After Coronary Artery Bypass Graft (CABG)
Nuclear cardiology techniques are extremely useful in patients post 
CABG. Besides helping in the selection of patients for surgical 
revascularization, they can be used to: 
Check for perioperative myocardial infarction.
Document improvement in myocardial perfusion and function after 
surgery.
Demonstrate graft occlusion and ischemia due to incomplete 
revascularization or progression of disease.
Predict future cardiac events.
The risk of graft occlusion is approximately 12% to 20% after the fi rst 
year.(17) Independently of the technique used for CABG, graft patency 
can be accurately assessed with MPI, with a high correlation between 
myocardial perfusion scintigraphic and angiographic fi ndings,(18-20) with 
sensitivity and accuracy superior to those of Stress ECG fi ndings.(21)
In a study done in Johannesburg, South Africa evaluating 142 patients 
post CABG for ischemia, 68% of  those asymptomatic were found to 
have ischemia on MPI.(22)
Stress imaging may distinguish patients with noncoronary chest pain 
from those with signifi cant myocardial ischemia. Regardless of symptoms, 
normal results on a post-CABG stress perfusion scan essentially exclude 
signifi cant graft stenosis.(18-20)                                     
Assessment of myocardial viability
While improvements are made to treat acute coronary syndromes, 
decreasing its initial mortality, there is an increased prevalence of 
■
■
■
■
■
■
■
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patients with left ventricular dysfunction. These patients are at risk for 
severe morbidities, recurrent hospitalizations, cardiac death and severe 
lifestyle limitations.
LV dysfunction as a result of ischemic heart disease is not always due 
to irreversible myocardial necrosis or scarring. Ischemic injury can lead 
to left ventricular dysfunction through different processes like LV 
remodeling, impairment of metabolism, myocyte dysfunction or cell 
death due to necrosis or apoptosis.(23)
Besides the case of cell death, these processes can be reversible, with 
various degrees improvement in left ventricular function. Appropriate 
medial therapy and often revascularization in properly selected patients 
can represent the best therapeutic approach.
Stunned myocardium is defi ned as myocardium dysfunctional due 
to a transient coronary occlusion, salvaged by coronary reperfusion but 
still exhibiting prolonged but transient post ischemic dysfunction. So 
even though the blood fl ow has been restored, contraction has still not 
improved; that means there is a fl ow-contraction mismatch.(24)  This can 
happen as a result of an acute myocardial infarction followed by 
reperfusion, after ischemia (spontaneous or exercise induced), after 
cardioplegic arrest during heart surgery.
Hibernating myocardium is defi ned as a state of persistently 
impaired left ventricular function at rest due to reduced coronary 
blood fl ow. Therefore, hibernating myocardium has a fl ow-contraction 
match.(25)
Patients with depressed left ventricular function have a worse prognosis 
than patients whose left ventricular function is normal.(26) The 
importance of myocardial viability assessment is to identify those 
patients with hibernating or stunned myocardium because ventricular 
function as well as symptoms and natural history may improve after 
revascularization. Although PET metabolic imaging with 18F-FDG has 
been considered the “gold standard” for evaluating myocardial viability 
for years, other radiotracers have been proven to have a high 
accuracy.
In a study done by Di Carli et al. with PET in patients with coronary 
artery disease and mean left ventricular ejection fraction of 25%, those 
with myocardial viability had a 50% annual survival when treated 
medically vs. 88% when treated with revascularization. Those patients 
that showed no viability on scan had 92% annual survival when treated 
medically vs. 50% when revascularized.(27)
In a meta-analysis by Allman KC et al. of 3 088 patients with decreased 
left ventricular ejection fraction that underwent viability study using 
different methods, those with viable myocardium showed an annual 
death rate of 3.2% when sent for revascularization and 16% when 
treated medically (p=0.0001), as opposed to those with no viable 
myocardium who had a 7.7% death rate when revascularized against 
6.2% when medical treatment was chosen (p=0.23).(28)
Hass F et al. in a PET imaging study of patients with coronary artery 
disease and LV dysfunction considered for CABG concluded that the 
forgoing of a viability study resulted in too many high-risk patients 
without viability being sent for bypass surgery, resulting in a worse 
prognosis.(29)
Currently several radionuclide techniques are available to evaluate 
myocardial viability:
Stress-delayed Tl-201
Rest-delayed Tl-201
Tc-99m Sestamibi
Positron Emission Tomography (PET) metabolic imaging with 
18F-FDG
In a meta-analysis of 33 studies with Tl-201done by Bax JJ et al., sensitivity 
was found to be 86% and specifi city 59%, while in 20 studies in which 
patients were evaluated using Tc-99m Sestamibi they were 81% and 
86% respectively. The positive predictive value was 71% and negative 
predictive value 77%.(30) Collateral fl ow to the hypoperfused areas is 
improved by nitrates. When sestamibi imaging was nitrate-enhanced, 
sensitivity was 86% and specifi city 83%.(30) In an analysis of 18 studies 
directly comparing 563 patients who underwent viability assessment 
with a nuclear technique (Tl-201 or F-18-FDG PET) versus dobutamine 
echocardiography, Bax and coworkers reported that pooled results 
indicate: 
Higher sensitivity and negative predictive value for the nuclear 
technique.
Higher specifi city and positive predictive value for dobutamine 
echocardiography.(31)
■
■
■
■
■
■
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DiCarli et al. showed that the extent of the defect on PET imaging 
demonstrating hibernating myocardium can predict the functional 
recovery after revascularization.(31) PET is considered the “gold standard” 
for evaluation of viability using metabolic tracers. 
Using metabolic tracers, both perfusion and regional function can be 
evaluated.  It may be misleading to consider viability simply based on its 
presence or absence,(32) as it can exist in a range of situations, from 
necrosis due to infarction, which would represent non-recoverable 
myocardium, to transmural stunning or hibernation with prospective of 
full recovery .  
DiCarli et al. established that the area of myocardial viability is related 
to the percentage of left ventricular function improvement post-
revascularization. The larger the area, the greater the improvement.(31)
Pharmacological Stress Testing
As physical stress is not possible in many patients, either because they 
cannot achieve at least 85% of the target heart rate or because there 
are contraindications to the test (Table 3), pharmacological stress can 
be used as an appropriate alternative.
The pathophysiological basis for the use of coronary vasodilators is that 
in the presence of a narrowing in a coronary artery, the capacity to 
increase the myocardial blood fl ow with pharmacologic stimulation is 
decreased with inverse relation to the severity of the stenosis, causing 
a heterogeneous tracer uptake by the myocardium, with reduced 
uptake in the area supplied by the affected artery.
Several coronary vasodilators can be used:
Adenosine
Dipyridamole
Adenosine triphosphate
Other agents, such as a selective A2 agonist.
In South Africa dipyridamole and adenosine are the pharmacological 
agents of choice. In case of contraindication to dipyridamole or 
adenosine, inotropic/chronotropic agents like dobutamine can be 
selected (see Table 4).
Adenosine
The mode of action is by activation of A2 receptors, which causes 
coronary vasodilatation through the production of adenylate cyclase 
and cyclic AMP stimulation of K+ channels. Reduction of intracellular 
calcium also occurs.
Dipyridamole
Acts by blocking the transport of adenosine into the cells, its uptake 
across the cell membrane and its metabolism, raising endogenous 
adenosine levels. 
■
■
■
■
TABLE 3: Contraindications to exercise stress testing
Peripheral vascular disease
Arthritis
Cerebral-vascular disease
Orthopedic problems 
Chronic pulmonary disease
Extremity amputation
Poor motivation to exercise 
Poor exercise capacity 
Beta-blocking drugs that limit heart rate response
Left bundle-branch block
Early after myocardial infarction (<5 days)
From Beller GA, Pharmacological stress imaging in clinical nuclear cardiology, Philadelphia, 1995, WB 
Saunders Company.
To Adenosine or Dipyridamole 
Bronchospasm
Hypotension at baseline (systolic BP <90 mm Hg)
 Acute myocardial infarction (within 24 hours)
 Acute coronary syndromes
 Second degree or higher A-V block (in the absence of a pacemaker)
 Hypersensitivity reaction
To Dobutamine
Severe hypotension or hypertension
Uncontrolled atrial fl utter or fi brillation
Recurrent ventricular tachycardia 
Severe left ventricular outfl ow obstruction
Recent acute myocardial infarction
Acute coronary syndromes
Large aortic aneurysms
Decompensated heart failure
TABLE 4:  Contraindications to pharmacological agents
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This causes coronary vasodilatation with minor decrease in peripheral 
vascular resistance. Its effects are reversed by aminophylline by 
competition for the receptor binding sites.
Dobutamine
This is a powerful inotropic agent whose onset of action is at 1 – 2 
minutes with the peak effect being achieved several minutes later.
Sensitivity and specifi city for dipyridamole has been found to be 89% 
and 78%, for adenosine 90% and 91%, and for dubutamine 82% and 
73%.(33-49)
It is better to do an appropriate pharmacological stress when indicated, 
rather than an insuffi cient exercise test (Figure 1). 
DISCUSSION
Literature has shown that it is not the coronary anatomy but the 
ischemic burden that determines risk.(50) The physician’s goal at present 
time is not so much identifying the patients with anatomic CAD, but 
predicting which patients are at risk for adverse events, i.e. cardiac 
death or nonfatal MI, and  deciding  management strategies that might 
reduce the risk of these outcomes after MPI. This risk-based approach 
includes not only symptomatic but also asymptomatic patients with 
suspected ischemic heart disease.(51)
In South Africa myocardial perfusion imaging (MPI) is underused, 
probably due to the underexposure and undertraining of cardiologists 
in these extremely valuable techniques. Consequently, too many patients 
end up in the catheterization lab, whether for diagnostic purposes, or 
for follow-up of patients with known ischemic heart disease, for 
reevaluation when they present with new symptoms after myocardial 
infarction, percutaneous interventions or CABG. 
According to a statement by the American Society of Nuclear 
Cardiology published in 1997, a normal perfusion scan predicts a <1% 
risk of adverse events (myocardial infarction or cardiac death) for a 
period of at least 12 months, independently of gender, age, symptoms, 
history of coronary artery disease, presence of anatomic CAD or 
isotope or imaging technique used.(52) Other publications state that 
event rates following  a normal MPI can be infl uenced by age and 
comorbidity taking the hard event rates to between 1.3% and 2.7% in 
elderly patients stressed pharmacologically.(52-55)
Still, as a group, patients with a normal MPI study are at very low risk of 
hard event during the fi rst year post-test.(56)
When an MPI is found to be abnormal, the risk for hard events is 
related to the severity of the abnormality; the greater the affected area, 
the higher the risk.(51,57-66)
Hachamovitch et al. found that patients with a mildly abnormal scan 
were at intermediate risk for myocardial infarction (2.7%) but low risk 
for cardiac death (0.8%).(60) If the patients had to undergo pharmacological 
testing for any reason, or are elderly, have previous history of CAD, 
diabetes mellitus or atrial fi brillation, even with a mildly abnormal scan, 
the risk is increased.(55,59,67,68,69)
In studies done by Albro PC et al., and Hachamovitch R et al., when the 
scan is found to be moderate and severely abnormal, the risk for 
myocardial infarction and cardiac death correlates with the degree of 
the coronary stenosis supplying those territories and depends on the 
severity and extent of the perfusion defects.(70,71)
Fixed and reversible stress perfusion defects predict hard events; still, 
patients with extensive stress-induced defects are the ones at higher 
risk.(57-60,62,63,65,71-73)
Perfusion defects are not the only determinants of risk. When MPI is 
performed with 201-Tl, abnormally increased tracer uptake of the 
FIGURE 1: Stress-rest MPI studies showing severe apical, apical-anterior, mid-
anterior, mid-anteroseptal and basal-anteroseptal segments, stress induced ischemia 
(Short axis, vertical long axis and horizontal long axis views.  Upper row corresponds 
to stress study; lower row corresponds to rest study).
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tracer by the lungs is considered to be secondary to elevated pulmonary 
capillary wedge pressure, caused by ischemia or left ventricular 
claudication from a nonischemic etiology. This fi nding has been 
shown to add prognostic information over the perfusion defects.(74) 
Independently of the pharmacological agent used to perform the MPI, 
left ventricular transient ischemic dilation (TID) is present when the 
cavity in the post-stress is found to be signifi cantly larger than in the rest 
images.  The fi nding is considered to be caused by diffuse subendocardial 
ischemia which causes apparent cavity dilation.(71)
TID is a marker of risk and it has been found to add incrementally over 
perfusion data.(66,75,76)
The approach suggested by R. Hachamovitch and D. Berman(67,71)  based 
on published evidence, is to manage patients with normal scans 
medically, as revascularization has not been shown to provide potential 
benefi t in mortality. Patients whose MPIs show reversible perfusion 
defects extending to <10% of the myocardium (mild to moderate 
ischemia) should be managed medically including risk factor modifi cation 
too, as revascularization will not provide a mortality benefi t. If however 
they are symptomatic and the symptoms impact negatively on their 
quality of life, or if they have additional markers of severity such as 
increased pulmonary accumulation of 201Tl or TID, they should be 
referred for catheterization with a view to intervention.(67,71)
When the extent of the ischemic myocardium is 10-20% or >20%, 
patients have been found to have improved prognosis with 
revascularization as compared to medical treatment. Due to their 
higher risk for adverse events, the authors recommend these groups of 
patients to undergo catheterization, to assess the need for revas-
cularization.(67,71)
CONCLUSION
Myocardial perfusion imaging constitutes a highly valuable technique in 
the diagnosis of coronary artery disease, especially in patients with 
intermediate pretest likelihood. As it has been shown that patients’ 
prognosis is determined by the ischemic burden, the information 
provided by MPI is seminal in patients with known ischemic heart 
disease for risk stratifi cation (decision making), to assess the best 
possible management,  medical or  revascularization. 
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